Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About


Published July 29, 2018
Published July 29, 2018
Chuttersnap via Unsplash

Beiersdorf, the Germany-based personal care manufacturer that owns brands such as Nivea, Eucerin, La Prairie, and Labello, has made an equity investment into S-Biomedic, a Belgium-based life science company, with the intention to drive the future of skincare through research into the skin microbiome.

WHO: S-Biomedic is a Belgium-based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. In this field, S-Biomedic has developed a lead program focusing on acne. Simultaneously, two early-stage concept development programs have been initiated focusing on aging and dandruff. S-Biomedic is a resident at Johnson & Johnson Innovation, JLABS in Beerse.

Beiersdorf is a German personal-care company based in Hamburg, manufacturing personal-care products and pressure-sensitive adhesives. Its brands include Elastoplast, Eucerin (makers of Aquaphor), Labello, La Prairie, and Nivea.

IN THEIR OWN WORDS: “Since 1882, Beiersdorf has been successfully building partnerships with suppliers, universities, research institutions, as well as individual inventors and innovators,” emphasized Ralph Gusko, Board Member for Consumer Brands at Beiersdorf. “With our investment into S-Biomedic, we open up for cooperations with start-up companies. These pioneers for future technologies will help us deliver answers for unmet consumer needs.”

“Skin Care is on the verge of disruption and will hugely benefit from the dramatic progress in life science research. Microbiome research is one of the most dynamic fields, and we need to deeply look at it for innovative offers for our consumers,” said Dr. May Shana’a, Senior Corporate Vice President of R&D for Beiersdorf. “We are delighted to tap into Beiersdorf’s vast experience in skin care to take our research to the next stage of commercialization with maximum speed and efficiency,” said Veronika Oudova, CEO of S-Biomedic.


  • Beiersdorf has made an equity investment into S-Biomedic.
  • Accordingly, Beiersdorf has taken an equity investment into S-Biomedic in the single-digit million-euro range.

2 Article(s) Remaining

Subscribe today for full access